Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
CP-316819 has been used as a positive control to study the inhibitory activity against glycogen phosphorylase in vitro.
Biochem/physiol Actions
CP-316819 belongs to the family of indole-2-carboxamide series of phosphorylase inhibitors. It has an ability to regulate interaction of glycogen targeting subunit (GL) 16mer peptide with phosphorylase a.
CP-316819 is a potent glycogen phosphorylase inhibitor. (IC50 = 40 nM against human liver GPα.) Under low glucose conditions, CP-316819 facilitates glycogen utilization in the brain, prevents neuronal cell death and maintains brain electrical currents.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :